Prof. Christoph Borchers1,2,3
(1) Skolkovo Institute of Science and Technology (Skoltech), Center for Computational and Data-Intensive Science and Engineering/Laboratory of Omics Technologies and Big Data for Personalized Medicine and Health.
(2) Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
(3) Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Prof Jose Luis Capelo1,2
New University of Lisbon
(1) Bioscope Group, LAQV@ Requimte, Chemistry Department, Faculty of Science and Technology, NOVA University of Lisbon, 2825-466 Almada Portugal
(2) Proteomass Scientific Society, 2825-466 Costa de Caparica, Portugal.
Prof. Luis Zerbini
Cancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa. luiz.zerbini@icgeb.org
Dr. Stefano Cacciatore1,2
(1) Cancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa
(2) Institute for Reproductive and Developmental Biology, Imperial College, London, UK.
Prof. Jonathan M Blackburn1,2
(1) Division of Chemical & Systems Biology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town. South Africa
(2) Institute of Infectious Disease & Molecular Medicine, Faculty of Health Sciences, University of Cape Town. South Africa
